Katarina Kolostova1, Eliska Pospisilova1, Rafal Matkowski2,3, Jolanta Szelachowska2,3, Vladimir Bobek4,5,6,7. 1. Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. 2. Department of Oncology, Wrocław Medical University, Wrocław, Poland. 3. Breast Cancer Unit, Lower Silesian Oncology, Pulmonology and Hematology Center, Plac Hirszfelda 12, 54-413, Wrocław, Poland. 4. Laboratory of Personalized Medicine, Oncology Clinic, University Hospital Kralovske Vinohrady, Srobarova 50, 10034, Prague, Czech Republic. vbobek@centrum.cz. 5. 3rd Department of Surgery University Hospital Motol and 1st Faculty of Medicine, Charles University, V Uvalu 84, 15006, Prague, Czech Republic. vbobek@centrum.cz. 6. Department of Thoracic Surgery, Masaryk's Hospital, Krajska Zdravotni a.s., Socialni pece 3316/12A, 40113, Usti nad Labem, Czech Republic. vbobek@centrum.cz. 7. Department of Thoracic Surgery, Lower Silesian Oncology, Pulmology and Hematology Center and Medical University Wroclaw, Grabiszynska 105, 53-413, Wrocław, Poland. vbobek@centrum.cz.
Abstract
BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
BACKGROUND: Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. METHODS: DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy® separation protocols (Miltenyi Biotec). For differentiation and maturation of CD14 + cells, DendriMACs® growing medium with supplements (GM-CSF, IL-4, IL-6, IL-1B, TNFa, PGE) was used. Immature Mo-DCs were loaded with autologous circulating tumor cell (CTCs) lysates. Autologous CTCs were sorted out by size-based filtration (MetaCell®) of the leukapheresis CD14-negative fraction. A mixture of mature Mo-DCs and autologous non-target blood cells (NTBCs) was co-cultured and the activation effect of mature Mo-DCs on T-cell activation was monitored by means of multimarker gene expression profiling. RESULTS: New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). CONCLUSION: Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
Authors: Axel Heiser; Doris Coleman; Jens Dannull; Donna Yancey; Margaret A Maurice; Costas D Lallas; Philipp Dahm; Donna Niedzwiecki; Eli Gilboa; Johannes Vieweg Journal: J Clin Invest Date: 2002-02 Impact factor: 14.808
Authors: Katarina Kolostova; Rafał Matkowski; Marcin Jędryka; Katarzyna Soter; Martin Cegan; Michael Pinkas; Anna Jakabova; Jiri Pavlasek; Jan Spicka; Vladimir Bobek Journal: Am J Cancer Res Date: 2015-10-15 Impact factor: 6.166